Summary of Mineralys Therapeutics Q2 2026 Earnings Call

1Key Financial Results and Metrics

Cash Position: As of June 30, 2026, Mineralys reported cash, cash equivalents, and investments of $661.4 million, slightly up from $656.6 million at the end of 2025.

R&D Expenses: Increased significantly to $221.4 million from $38.3 million in Q2 2025, primarily due to a $200 million upfront payment to Mitsubishi Tanabe Pharma for a royalty repurchase agreement.

G&A Expenses: Rose to $24.7 million from $8.5 million in Q2 2025, driven by higher professional fees and personnel-related costs.

Net Loss: Expanded to $241.1 million from $43.3 million in the prior year, reflecting increased expenses.

Other Income: Total other income was $5 million, up from $3.5 million, mainly due to increased interest earned on investments.

2Strategic Updates and Business Highlights

Leadership Change: Dr. Terry Ferguson was appointed as Chief Medical Officer, succeeding Dr. David Rodman, who will remain as a strategic adviser.

Commercial Launch Readiness: The company is focused on preparing for the commercial launch of lorundrostat, with a PDUFA date set for December 22, 2026.

Clinical Progress: Continued to gather long-term safety and efficacy data from the Transform HTN trial and presented promising results at recent medical conferences, particularly regarding patients with chronic kidney disease.

Royalty Repurchase Agreement: The company repurchased potential future royalty payments from Mitsubishi Tanabe for $200 million upfront, with additional milestone payments possible.

Equity Offering and Loan Facility: Completed a $150 million equity offering and secured a $500 million senior secured term loan, enhancing financial flexibility.

3Forward Guidance and Outlook

Mineralys believes it has sufficient capital to fund operations and the commercial launch of lorundrostat through 2028.

The company is optimistic about the potential of lorundrostat, citing its best-in-class profile and significant unmet need in the hypertension market.

Plans to continue evaluating clinical development opportunities for lorundrostat beyond hypertension, particularly in cardiorenal metabolic disorders.

4Bad News, Challenges, or Points of Concern

Increased Expenses: The substantial rise in R&D and G&A expenses raises concerns about financial sustainability, especially with a growing net loss.

Competition: The launch of baxdrostat by AstraZeneca poses a competitive threat, and there are concerns about how lorundrostat will differentiate itself in the market.

Payer Access: While initial payer engagement has been positive, there is uncertainty regarding the timing of Medicare coverage and potential delays in access for patients.

Market Pressure: The company faces pressure to establish a competitive pricing strategy in light of baxdrostat's pricing and market positioning.

5Notable Q&A Insights

Sales Force Recruitment: The quality of candidates for the sales team is reportedly high, with plans to have the team in place before the PDUFA date. The company is looking for candidates with cardiovascular experience and alignment with its values.

Payer Strategy: Payers are still evaluating lorundrostat, with expectations that coverage will improve progressively throughout 2027. The company is preparing to support prior authorizations to facilitate patient access.

Label Negotiations: Discussions with the FDA regarding the drug label are expected to begin in October or November, with hopes for a label that emphasizes lorundrostat's unique clinical data.

Guideline Updates: Anticipated updates to hypertension guidelines in 2027 could further validate the role of aldosterone synthase inhibitors in treatment. Overall, Mineralys Therapeutics is at a pivotal moment as it prepares for the potential launch of lorundrostat, while navigating financial challenges and competitive pressures in the hypertension market.